Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58].
Center for Congenital Heart Diseases, Department of Paediatric Cardiology, Beatrix Children's Hospital, University Medical Centre, Groningen, The Netherlands. Electronic address: r.m.f.berger@umcg.nl.
Rolf M F
RMF
Berger
Institute of Child Health, University College, London, UK.
Sheila G
SG
Haworth
M3C-Hospital Necker Enfants Malades, Department of Paediatric Cardiology, Université Paris Descartes, Paris, France.
Damien
D
Bonnet
Department of Paediatric Cardiology, Children's Hospital, Toulouse, France.
Yves
Y
Dulac
La Timone Children's Hospital, Department of Paediatric Cardiology, Marseille, France.
Alain
A
Fraisse
Institute of Cardiology, University of Bologna, Bologna, Italy.
Nazzareno
N
Galiè
Children's Hospital Colorado, Department of Pediatric Cardiology, Denver, CO, USA.
D Dunbar
DD
Ivy
Bicêtre Hospital, Department of Pneumology, Le Kremlin-Bicêtre, France.
Xavier
X
Jaïs
Deutsches Herzzentrum Berlin, Berlin, Germany.
Oliver
O
Miera
Columbia University, New York, NY, USA.
Erika B
EB
Rosenzweig
Actelion Pharmaceuticals srl, Department of Biostatistics, Imperia, Italy.
Michela
M
Efficace
Actelion Pharmaceuticals Ltd., Department of Clinical Science, Allschwil, Switzerland.
Andjela
A
Kusic-Pajic
Children's Hospital, Paediatric Cardiology Unit, University of Geneva, Geneva, Switzerland.
Maurice
M
Beghetti